Enterprise Value
300M
Cash
194.9M
Avg Qtr Burn
-18.84M
Short % of Float
5.09%
Insider Ownership
6.43%
Institutional Own.
86.09%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Acazicolcept (ALPN-101) Details Systemic lupus erythematosus | Phase 2 Data readout | |
Povetacicept (ALPN-303) Details Autoimmune disease, Autoimmune nephritis, Immune complex membranoproliferative glomerulonephritis | Phase 1b Data readout | |
Povetacicept (ALPN-303) Details Autoimmune disease, Primary immune thrombocytopenia | Phase 1b Data readout | |
Davoceticept (ALPN-202) (CD28 costimulator) Details Advanced malignancies | Failed Discontinued |